Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Chan Zuckerberg Biohub is both an institute and an academic network devoted to accelerating research via cutting edge technologies and open science. Its focus on single-cell analysis and infectious disease has placed it front and center in the pandemic.
Four antibodies are already in trials to test efficacy against the emerging checkpoint molecule TIGIT, but debate swirls around the importance of Fc binding for drug action.
A deep brain stimulation device capable of fine-tuning output on the basis of patient neuronal activity has been approved for the first time for use in Parkinson’s and a range of other neurological disorders.
Initiatives to gather massive epidemiological datasets aim to cut through national COVID-19 stats in a bid to understand the new coronavirus and aid public health policymakers.
The interaction between patents and FDA’s De Novo and 510(k) regulatory pathways has the potential to threaten follow-on innovation for medical devices.
A new workshop brings together under-represented participants to gain experience working in diverse teams, identifying problems worth solving, and learning evidence-based entrepreneurship approaches.
The pandemic has highlighted long-standing, deep-rooted challenges to the sharing of biological samples. Greater attention is needed to mechanisms for incentivizing materials transfer.
Single-cell analysis sheds light on immune response to COVID-19 infection, enables the rapid discovery of antibody leads, and points to ways to get ahead of future pandemics.